CD8A and non-small cell lung carcinoma: Another study in NSCLC patients treated with nivolumab showed the CD4+ and CD8+ central memory T cell (CM) / Effector T cell (Eff) ratio in blood is useful to correlate with treatment response to anti-PD-1 immunotherapy.